Trials / Unknown
UnknownNCT05433194
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (Omicron) mRNA Vaccine (ABO1009-DP) for Sequential Immunization in the Population Aged 18 Years and Older Who Have Completed the Full Vaccination
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
A Phase I clinical study to evaluate the safety, tolerability, and immunogenicity of SARS-CoV-2 variant (Omicron) mRNA vaccine which is used to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABO1009-DP | Vaccine |
Timeline
- Start date
- 2022-08-22
- Primary completion
- 2022-09-26
- Completion
- 2023-08-25
- First posted
- 2022-06-27
- Last updated
- 2023-02-08
Locations
1 site across 1 country: United Arab Emirates
Source: ClinicalTrials.gov record NCT05433194. Inclusion in this directory is not an endorsement.